NCT03093064 - Inflammatory Response In Schizophrenia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 1, 2017

Primary Completion Date

June 15, 2023

Study Completion Date

August 7, 2023

Conditions

Schizophrenia

Interventions

DRUG

Natalizumab

Natalizumab is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin, currently licensed for the treatment of multiple sclerosis and Crohn's disease.

OTHER

Placebo: normal saline

Normal saline, intravenous infusion

Trial Locations (1)

SE5 8AF

Institute of Psychiatry, Psychology and Neuroscience, King's College London, London

All Listed Sponsors

collaborator

South London and Maudsley NHS Foundation Trust

OTHER

lead

King's College London

OTHER